A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s diseaseStephen Salloway, Paul Aisen, Kelley A. Coalier et al.|Nature Medicine|2021Cited by 365
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C→T (Arg493X) mutation: an international initiativeRosa Rademakers, Mike Hutton, Matt Baker et al.|The Lancet Neurology|2007Cited by 217
Identification of evolutionarily conserved gene networks mediating neurodegenerative dementiaVivek Swarup, Christer Nilsson, Flora I. Hinz et al.|Nature Medicine|2018Cited by 156
Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trialSusan Mills, Randall J. Bateman, J. Mallmann et al.|Revue Neurologique|2013Cited by 136
Amyloid‐Related Imaging Abnormalities in the <scp>DIAN‐TU</scp>‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph‐Mathurin, Richard J. Perrin, Jorge J. Llibre‐Guerra et al.|Annals of Neurology|2022Cited by 42